immunomagnetic negative selection kits cat Search Results


97
Miltenyi Biotec pan t cell negative selection kit
Pan T Cell Negative Selection Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan t cell negative selection kit/product/Miltenyi Biotec
Average 97 stars, based on 1 article reviews
pan t cell negative selection kit - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier

90
Sino Biological immunomagnetic beads
Immunomagnetic Beads, supplied by Sino Biological, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/immunomagnetic beads/product/Sino Biological
Average 90 stars, based on 1 article reviews
immunomagnetic beads - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
StemCells Inc immunomagnetic positive selection kits 18053
Immunomagnetic Positive Selection Kits 18053, supplied by StemCells Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/immunomagnetic positive selection kits 18053/product/StemCells Inc
Average 90 stars, based on 1 article reviews
immunomagnetic positive selection kits 18053 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc easysep immunomagnetic negative selection kit
Easysep Immunomagnetic Negative Selection Kit, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/easysep immunomagnetic negative selection kit/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
easysep immunomagnetic negative selection kit - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

97
Miltenyi Biotec immunomagnetic negative selection based separation
Figure 2. Comparison of viability and purity after the different <t>separation</t> techniques. Viability was determined with 7-AAD staining while purity was expressed as a percentage of <t>CD4+</t> cells in the living cell population (see Methods). Measurements were made via flow cytometry, subsequently after the separation (values are plotted as mean±SD for the number of independent experiments indicated in the bar). No significant differences were found among the groups for either viability or purity (one-way analysis of variance, p > 0.05). REAlease®: measured after the complete removal of bead-antibody and REAlease® complex, in label-free configuration (see Figure 1), Negative selection: <t>immunomagnetic</t> negative selection, Sorted: positive selection by flow cytometry.
Immunomagnetic Negative Selection Based Separation, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/immunomagnetic negative selection based separation/product/Miltenyi Biotec
Average 97 stars, based on 1 article reviews
immunomagnetic negative selection based separation - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc immunomagnetic negative selection kits cat# 17951
Figure 2. Comparison of viability and purity after the different <t>separation</t> techniques. Viability was determined with 7-AAD staining while purity was expressed as a percentage of <t>CD4+</t> cells in the living cell population (see Methods). Measurements were made via flow cytometry, subsequently after the separation (values are plotted as mean±SD for the number of independent experiments indicated in the bar). No significant differences were found among the groups for either viability or purity (one-way analysis of variance, p > 0.05). REAlease®: measured after the complete removal of bead-antibody and REAlease® complex, in label-free configuration (see Figure 1), Negative selection: <t>immunomagnetic</t> negative selection, Sorted: positive selection by flow cytometry.
Immunomagnetic Negative Selection Kits Cat# 17951, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/immunomagnetic negative selection kits cat# 17951/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
immunomagnetic negative selection kits cat# 17951 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

96
Miltenyi Biotec ultrapure cd34 microbead kit
a , b Mutant allele burden change (%) in ( a ) responders achieving after 24w tamoxifen treatment allele burden reductions of ≥50% ( n = 3, green) or ≥25%, <50% ( n = 5, orange), and ( b ) in non-responders ( n = 28, red) before treatment, and 12w or 24w after tamoxifen administration. c - d HSPCs measured <t>as</t> <t>colony-forming</t> <t>units</t> in culture (CFU-Cs) from study patients’ peripheral blood mononuclear cells treated with 4OH-TAM (10 mM) or vehicle for 24 h. Reduced ( c ) or unchanged ( d ) HSPC numbers upon ex vivo 4OH-TAM treatment of baseline samples are consistent with the allele burden reductions observed in the same patients after 24w tamoxifen treatment ( c , green ≥ 50%, n = 2; orange≥25%, n = 1; d , red < 25%, n = 5). * p < 0.05, two-tailed unpaired t test. e CFU-C genotyping shows a reduced balance of JAK2 V617F+ colonies, compared with WT colonies, by 4OH-TAM treatment in responders’, but not in non-responders’ samples (allele burden reductions after 24w are marked with green ≥ 50%, n = 1; orange ≥ 25%, n = 2; red < 25%, n = 3). ** p < 0.01, two-tailed paired t test. Data are mean ± SEM. f Heatmap reveals the disparity of gene expression between responders and non-responders at baseline. g , h Integrated pathway enrichment map using gene-sets enriched in responders ( g ) and non-responders ( h ). i , l Gene set enrichment analysis (GSEA) shows a higher activation of HSPCs in responders, with increased expression of ( i ) STAT3-, ( j ) STAT5-, ( k ) inflammation- and ( l ) apoptosis-related genes. NES, normalized enrichment score. FWER, family-wise error rate.
Ultrapure Cd34 Microbead Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ultrapure cd34 microbead kit/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
ultrapure cd34 microbead kit - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

96
Miltenyi Biotec cd90 2 positive immunomagnetic selection kit
a , b Mutant allele burden change (%) in ( a ) responders achieving after 24w tamoxifen treatment allele burden reductions of ≥50% ( n = 3, green) or ≥25%, <50% ( n = 5, orange), and ( b ) in non-responders ( n = 28, red) before treatment, and 12w or 24w after tamoxifen administration. c - d HSPCs measured <t>as</t> <t>colony-forming</t> <t>units</t> in culture (CFU-Cs) from study patients’ peripheral blood mononuclear cells treated with 4OH-TAM (10 mM) or vehicle for 24 h. Reduced ( c ) or unchanged ( d ) HSPC numbers upon ex vivo 4OH-TAM treatment of baseline samples are consistent with the allele burden reductions observed in the same patients after 24w tamoxifen treatment ( c , green ≥ 50%, n = 2; orange≥25%, n = 1; d , red < 25%, n = 5). * p < 0.05, two-tailed unpaired t test. e CFU-C genotyping shows a reduced balance of JAK2 V617F+ colonies, compared with WT colonies, by 4OH-TAM treatment in responders’, but not in non-responders’ samples (allele burden reductions after 24w are marked with green ≥ 50%, n = 1; orange ≥ 25%, n = 2; red < 25%, n = 3). ** p < 0.01, two-tailed paired t test. Data are mean ± SEM. f Heatmap reveals the disparity of gene expression between responders and non-responders at baseline. g , h Integrated pathway enrichment map using gene-sets enriched in responders ( g ) and non-responders ( h ). i , l Gene set enrichment analysis (GSEA) shows a higher activation of HSPCs in responders, with increased expression of ( i ) STAT3-, ( j ) STAT5-, ( k ) inflammation- and ( l ) apoptosis-related genes. NES, normalized enrichment score. FWER, family-wise error rate.
Cd90 2 Positive Immunomagnetic Selection Kit, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd90 2 positive immunomagnetic selection kit/product/Miltenyi Biotec
Average 96 stars, based on 1 article reviews
cd90 2 positive immunomagnetic selection kit - by Bioz Stars, 2026-05
96/100 stars
  Buy from Supplier

90
STEMCELL Technologies Inc immunomagnetic negative selection kit cat# 19055
a , b Mutant allele burden change (%) in ( a ) responders achieving after 24w tamoxifen treatment allele burden reductions of ≥50% ( n = 3, green) or ≥25%, <50% ( n = 5, orange), and ( b ) in non-responders ( n = 28, red) before treatment, and 12w or 24w after tamoxifen administration. c - d HSPCs measured <t>as</t> <t>colony-forming</t> <t>units</t> in culture (CFU-Cs) from study patients’ peripheral blood mononuclear cells treated with 4OH-TAM (10 mM) or vehicle for 24 h. Reduced ( c ) or unchanged ( d ) HSPC numbers upon ex vivo 4OH-TAM treatment of baseline samples are consistent with the allele burden reductions observed in the same patients after 24w tamoxifen treatment ( c , green ≥ 50%, n = 2; orange≥25%, n = 1; d , red < 25%, n = 5). * p < 0.05, two-tailed unpaired t test. e CFU-C genotyping shows a reduced balance of JAK2 V617F+ colonies, compared with WT colonies, by 4OH-TAM treatment in responders’, but not in non-responders’ samples (allele burden reductions after 24w are marked with green ≥ 50%, n = 1; orange ≥ 25%, n = 2; red < 25%, n = 3). ** p < 0.01, two-tailed paired t test. Data are mean ± SEM. f Heatmap reveals the disparity of gene expression between responders and non-responders at baseline. g , h Integrated pathway enrichment map using gene-sets enriched in responders ( g ) and non-responders ( h ). i , l Gene set enrichment analysis (GSEA) shows a higher activation of HSPCs in responders, with increased expression of ( i ) STAT3-, ( j ) STAT5-, ( k ) inflammation- and ( l ) apoptosis-related genes. NES, normalized enrichment score. FWER, family-wise error rate.
Immunomagnetic Negative Selection Kit Cat# 19055, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/immunomagnetic negative selection kit cat# 19055/product/STEMCELL Technologies Inc
Average 90 stars, based on 1 article reviews
immunomagnetic negative selection kit cat# 19055 - by Bioz Stars, 2026-05
90/100 stars
  Buy from Supplier

97
Miltenyi Biotec immunomagnetic beads
a , b Mutant allele burden change (%) in ( a ) responders achieving after 24w tamoxifen treatment allele burden reductions of ≥50% ( n = 3, green) or ≥25%, <50% ( n = 5, orange), and ( b ) in non-responders ( n = 28, red) before treatment, and 12w or 24w after tamoxifen administration. c - d HSPCs measured <t>as</t> <t>colony-forming</t> <t>units</t> in culture (CFU-Cs) from study patients’ peripheral blood mononuclear cells treated with 4OH-TAM (10 mM) or vehicle for 24 h. Reduced ( c ) or unchanged ( d ) HSPC numbers upon ex vivo 4OH-TAM treatment of baseline samples are consistent with the allele burden reductions observed in the same patients after 24w tamoxifen treatment ( c , green ≥ 50%, n = 2; orange≥25%, n = 1; d , red < 25%, n = 5). * p < 0.05, two-tailed unpaired t test. e CFU-C genotyping shows a reduced balance of JAK2 V617F+ colonies, compared with WT colonies, by 4OH-TAM treatment in responders’, but not in non-responders’ samples (allele burden reductions after 24w are marked with green ≥ 50%, n = 1; orange ≥ 25%, n = 2; red < 25%, n = 3). ** p < 0.01, two-tailed paired t test. Data are mean ± SEM. f Heatmap reveals the disparity of gene expression between responders and non-responders at baseline. g , h Integrated pathway enrichment map using gene-sets enriched in responders ( g ) and non-responders ( h ). i , l Gene set enrichment analysis (GSEA) shows a higher activation of HSPCs in responders, with increased expression of ( i ) STAT3-, ( j ) STAT5-, ( k ) inflammation- and ( l ) apoptosis-related genes. NES, normalized enrichment score. FWER, family-wise error rate.
Immunomagnetic Beads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/immunomagnetic beads/product/Miltenyi Biotec
Average 97 stars, based on 1 article reviews
immunomagnetic beads - by Bioz Stars, 2026-05
97/100 stars
  Buy from Supplier

93
Miltenyi Biotec cd133 immunomagnetic beads
Figure 1. Light microscopy of A549 cells and SP cells (stained with <t>CD133+)</t> following A549 sorting. (A) Normal cultured A549 cells (x100 magnifica tion). (B) NSP cells were negatively stained by CD133, indicated by a green arrow. SP cells were positively stained by CD133, indicated by an orange arrow (x400 magnification). (C) The sorted SP cells (x100 magnification). (D) SP cells were positively stained by CD133, characterized by brown staining and indicated by an orange arrow (x400 magnification). SP, side population; NSP, non‑SP.
Cd133 Immunomagnetic Beads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd133 immunomagnetic beads/product/Miltenyi Biotec
Average 93 stars, based on 1 article reviews
cd133 immunomagnetic beads - by Bioz Stars, 2026-05
93/100 stars
  Buy from Supplier

Image Search Results


Figure 2. Comparison of viability and purity after the different separation techniques. Viability was determined with 7-AAD staining while purity was expressed as a percentage of CD4+ cells in the living cell population (see Methods). Measurements were made via flow cytometry, subsequently after the separation (values are plotted as mean±SD for the number of independent experiments indicated in the bar). No significant differences were found among the groups for either viability or purity (one-way analysis of variance, p > 0.05). REAlease®: measured after the complete removal of bead-antibody and REAlease® complex, in label-free configuration (see Figure 1), Negative selection: immunomagnetic negative selection, Sorted: positive selection by flow cytometry.

Journal: Channels (Austin, Tex.)

Article Title: Immunomagnetic separation is a suitable method for electrophysiology and ion channel pharmacology studies on T cells.

doi: 10.1080/19336950.2020.1859753

Figure Lengend Snippet: Figure 2. Comparison of viability and purity after the different separation techniques. Viability was determined with 7-AAD staining while purity was expressed as a percentage of CD4+ cells in the living cell population (see Methods). Measurements were made via flow cytometry, subsequently after the separation (values are plotted as mean±SD for the number of independent experiments indicated in the bar). No significant differences were found among the groups for either viability or purity (one-way analysis of variance, p > 0.05). REAlease®: measured after the complete removal of bead-antibody and REAlease® complex, in label-free configuration (see Figure 1), Negative selection: immunomagnetic negative selection, Sorted: positive selection by flow cytometry.

Article Snippet: Immunomagnetic negative selection-based separation (CD4+ T Cell Isolation Kit Cat. No.: 130–096-533 Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany) was prepared to isolate cells without labeling of the CD4 molecule, and these cells served as the “Control” configuration (Figure 1).

Techniques: Comparison, Staining, Flow Cytometry, Selection

a , b Mutant allele burden change (%) in ( a ) responders achieving after 24w tamoxifen treatment allele burden reductions of ≥50% ( n = 3, green) or ≥25%, <50% ( n = 5, orange), and ( b ) in non-responders ( n = 28, red) before treatment, and 12w or 24w after tamoxifen administration. c - d HSPCs measured as colony-forming units in culture (CFU-Cs) from study patients’ peripheral blood mononuclear cells treated with 4OH-TAM (10 mM) or vehicle for 24 h. Reduced ( c ) or unchanged ( d ) HSPC numbers upon ex vivo 4OH-TAM treatment of baseline samples are consistent with the allele burden reductions observed in the same patients after 24w tamoxifen treatment ( c , green ≥ 50%, n = 2; orange≥25%, n = 1; d , red < 25%, n = 5). * p < 0.05, two-tailed unpaired t test. e CFU-C genotyping shows a reduced balance of JAK2 V617F+ colonies, compared with WT colonies, by 4OH-TAM treatment in responders’, but not in non-responders’ samples (allele burden reductions after 24w are marked with green ≥ 50%, n = 1; orange ≥ 25%, n = 2; red < 25%, n = 3). ** p < 0.01, two-tailed paired t test. Data are mean ± SEM. f Heatmap reveals the disparity of gene expression between responders and non-responders at baseline. g , h Integrated pathway enrichment map using gene-sets enriched in responders ( g ) and non-responders ( h ). i , l Gene set enrichment analysis (GSEA) shows a higher activation of HSPCs in responders, with increased expression of ( i ) STAT3-, ( j ) STAT5-, ( k ) inflammation- and ( l ) apoptosis-related genes. NES, normalized enrichment score. FWER, family-wise error rate.

Journal: Nature Communications

Article Title: Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis

doi: 10.1038/s41467-023-43175-5

Figure Lengend Snippet: a , b Mutant allele burden change (%) in ( a ) responders achieving after 24w tamoxifen treatment allele burden reductions of ≥50% ( n = 3, green) or ≥25%, <50% ( n = 5, orange), and ( b ) in non-responders ( n = 28, red) before treatment, and 12w or 24w after tamoxifen administration. c - d HSPCs measured as colony-forming units in culture (CFU-Cs) from study patients’ peripheral blood mononuclear cells treated with 4OH-TAM (10 mM) or vehicle for 24 h. Reduced ( c ) or unchanged ( d ) HSPC numbers upon ex vivo 4OH-TAM treatment of baseline samples are consistent with the allele burden reductions observed in the same patients after 24w tamoxifen treatment ( c , green ≥ 50%, n = 2; orange≥25%, n = 1; d , red < 25%, n = 5). * p < 0.05, two-tailed unpaired t test. e CFU-C genotyping shows a reduced balance of JAK2 V617F+ colonies, compared with WT colonies, by 4OH-TAM treatment in responders’, but not in non-responders’ samples (allele burden reductions after 24w are marked with green ≥ 50%, n = 1; orange ≥ 25%, n = 2; red < 25%, n = 3). ** p < 0.01, two-tailed paired t test. Data are mean ± SEM. f Heatmap reveals the disparity of gene expression between responders and non-responders at baseline. g , h Integrated pathway enrichment map using gene-sets enriched in responders ( g ) and non-responders ( h ). i , l Gene set enrichment analysis (GSEA) shows a higher activation of HSPCs in responders, with increased expression of ( i ) STAT3-, ( j ) STAT5-, ( k ) inflammation- and ( l ) apoptosis-related genes. NES, normalized enrichment score. FWER, family-wise error rate.

Article Snippet: After ficoll centrifugation of blood, mononuclear cells were subjected to red blood cell lysis and CD34+ HSPCs were immunomagnetically isolated using the Ultrapure CD34 microbead kit (Miltenyi Biotec, Cat. No. 130-100-453) suing AUTOMACS (Miltenyi Biotec).

Techniques: Mutagenesis, Ex Vivo, Two Tailed Test, Gene Expression, Activation Assay, Expressing

Figure 1. Light microscopy of A549 cells and SP cells (stained with CD133+) following A549 sorting. (A) Normal cultured A549 cells (x100 magnifica tion). (B) NSP cells were negatively stained by CD133, indicated by a green arrow. SP cells were positively stained by CD133, indicated by an orange arrow (x400 magnification). (C) The sorted SP cells (x100 magnification). (D) SP cells were positively stained by CD133, characterized by brown staining and indicated by an orange arrow (x400 magnification). SP, side population; NSP, non‑SP.

Journal: Oncology letters

Article Title: Anticancer effects of curcumin on nude mice bearing lung cancer A549 cell subsets SP and NSP cells.

doi: 10.3892/ol.2018.9488

Figure Lengend Snippet: Figure 1. Light microscopy of A549 cells and SP cells (stained with CD133+) following A549 sorting. (A) Normal cultured A549 cells (x100 magnifica tion). (B) NSP cells were negatively stained by CD133, indicated by a green arrow. SP cells were positively stained by CD133, indicated by an orange arrow (x400 magnification). (C) The sorted SP cells (x100 magnification). (D) SP cells were positively stained by CD133, characterized by brown staining and indicated by an orange arrow (x400 magnification). SP, side population; NSP, non‑SP.

Article Snippet: Briefly, A549 cells were incubated with CD133 immunomagnetic beads (cat. no. 130-100-857; Miltenyi Biotec, Inc., Cambridge, MA, USA) for 30 min at 4 ̊C.

Techniques: Light Microscopy, Staining, Cell Culture